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Abstract 
Background: 5-year survival rate of oral tongue squamous cell carcinoma (OTSCC) 
has been low (less than 60%) despite developing treatment modalities. A previous 
research revealed that different populations of inflammatory cells infiltration in 
OTSCC were associated with different clinical outcomes. On the other hand, 
extracellular vesicles (EVs) secreted by OTSCC cells suggested crosstalk between 
OTSCC cells and tumor infiltrating inflammatory cells. 
Study aims: This study aims to investigate the interaction between OTSCC cells and 
inflammatory cells and answer 3 questions: (1) Can human peripheral blood 
mononuclear cells (MNCs) affect activities of OTSCC cells such as proliferation, 
migration and invasion? (2) Can EVs of OTSCC cells affect polarization of 
macrophages? (3) Can EVs of OTSCC cells affect cytotoxic activity of CD8+ T cells and 
NK cells? 
Materials and methods: Two OTSCC cell lines (HSC-3 and SCC-25) were used. OTSCC 
cells and human peripheral blood MNCs were co-cultured using a 3D organotypic 
myoma model. Proliferation and invasion into myoma tissue of OTSCC cells were 
detected by Immunohistochemical staining of pan-cytokeratin and Ki67. Invasion 
area and depth of OTSCC cells were measured using ImageJ software. Migration of 
OTSCC cells in the presence of MNCs was monitored using a scratch wound healing 
assay with IncuCyte™ system. OTSCC EVs were isolated with ultracentrifugation and 
characterized with NTA and Immuno-EM. Human primary monocytes, CD8+ T cells 
and NK cells were isolated using MACS, and their purity was checked using FACS. 
Expression of macrophage phenotypic markers was checked with qPCR. Cytotoxic 
activity was evaluated using an IncyCyte™ cell killing assay.  
Results: Activated human peripheral blood MNCs significantly reduced proliferation 
of both OTSCC cell lines, and invasion area of only HSC-3. None of the inflammatory 
cells in the experiment had any effect on invasion depth and migration of OTSCC 
cells. On the other hand, OTSCC cell-derived EVs didn’t influence macrophage 
II 
 
polarization, but had heterogeneous modulating effects on cytotoxic activity of CD8+ 
T cells and NK cells. 
Conclusion: We detected effects of OTSCC cells and inflammatory cells on each other 
by secreted molecule mediators or EVs, but the results were not uniform and varied 
in different OTSCC cell lines or inflammatory cell populations and sources. The 
outcome of the study emphasizes the importance of a personalized design of cancer 
treatment, which takes other components in tumor microenvironment such as 
inflammatory cells and EVs into consideration. 
Key words: oral tongue squamous cell carcinoma, cancer immunity, extracellular 
vesicles 
Additional information: Based on the data in this project one manuscript was 
written and now it is accepted for publication in Oncotarget (‘Crosstalk between 
tongue carcinoma cells, extracellular vesicles, and immune cells in in vitro and in 
vivo models’) 
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1. Literature review 
1.1. Oral tongue squamous cell carcinoma 
Over 90% of oral cancers are squamous cell carcinomas (Beenken & Urist, 2003). 
Possible sites of oral squamous cell carcinoma (OSCC) include gums, palate, floor of 
mouth, inner aspects of lips, as well as oral and basal tongue. Among those the most 
common site is the oral tongue (the anterior two thirds of the tongue, defined from 
basal tongue by a V-shaped groove named sulcus terminalis), accounting for over 
40% of all OSCC cases (Kirita & Omura, 2015). 
The tongue is an essential part in the oral cavity which functions in speech, eating, 
tasting and deglutition. It has a central core of a bunch of skeleton muscle bundles 
and is covered with a layer of epithelium. Tongue squamous cell carcinoma usually 
develop within the stratum spinosum layer of the epithelium. Like other cancers, 
normal keratinocytes of the tongue epithelium undergo a series of DNA mutations 
and acquire the ability to proliferate in an uncontrolled fashion. Once these 
keratinocytes invade through the basement membrane into the connective, muscle 
and adipose tissue, and even metastasize through the blood and lymph vessels, the 
malignancy process begins (Scully & Bagan, 2009; Kato & Shimizu, 2012; Weinberg, 
2013).  
1.1.1. Epidemiology and etiology of OSCC and OTSCC 
Oral cancer is globally among the eight most common cancers, with an increasing 
incidence. Each year over 300,000 new cases are diagnosed worldwide (Torre et al., 
2015). Specifically, the number of Finnish patients diagnosed for oral tongue 
squamous cell carcinoma (OTSCC) annually has approximately doubled from 1980 
to 2010 (Ng et al., 2016). Smoking and alcohol use are identified globally as the most 
representative risk factors for OSCC. Other etiological factors include smokeless 
tobacco, human papilloma virus (HPV), betel chewing, and poor dental health 
condition. Smoking is the top causative agent of oral cancer and it has been firmly 
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epidemiologically established (Murti et al., 1995; Kumar et al., 2016). The overall 
oral cancer risk of smokers is about 1.4 to 1.7 times higher than non-smokers 
(Hashibe et al., 2007). Additionally, when smoking and alcohol drinking are acting 
synergistically, the probability of developing an oral cancer is significantly raised 
(Radoï & Luce, 2013).  
Historically, males have been more susceptible to OSCC than females. The male-to-
female ratio was once as high as 6:1, yet gradually it has been now decreased to 2:1. 
The most probable explanation for the increased incidence among females is the 
growing number of female smokers and alcohol consumers (The Oral Cancer 
Foundation, 2017). In fact, in recent decades there has been an obvious trend that 
the average annual incidence increase of OSCC is higher in young female population 
(under 45) in many European countries and the States (Ng et al., 2016). Nowadays 
HPV, especially subtype 16, is becoming the primary carcinogenic factor of 
oropharyngeal cancers in non-smoking younger group (The Oral Cancer Foundation, 
2017). HPV is sexually transmitted between partners, also causing more than 90% 
of cervical cancers. The prevalence of HPV as an oral cancer carcinogenic factor 
reveals the change in sexual practice of young people. However, in case of OTSCC, 
HPV has not shown to be an etiological factor; the reason for the increased incidence 
of OTSCC among non-drinkers and non-smokers is not known (Salem, 2010). 
Conclusively, people’s choices of life style play important roles in the development 
of oral cancer. 
1.1.2. TNM staging, invasion and metastasis of OTSCC 
1.1.2.1 TNM staging system of OTSCC 
Clinically, OTSCC can be classified by TNM staging system according to 3 factors, 
which are the size of the primary tumor (T), location of the metastasis in regional 
lymph nodes (N) and presence of the distant metastasis (M) (Table 1). 
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Primary Tumor 
  TX 
  T0 
  Tis 
  T1 
  T2 
   
  T3 
  T4a 
 
 
  T4b 
 
 
 
Regional  
Lymph Nodes 
  NX 
  N0 
  N1 
 
  N2 
  N2a 
 
  N2b 
 
  N2c 
 
  N3 
 
Distant Metastasis 
 
Primary tumor cannot be assessed 
No evidence of primary tumor 
Carcinoma in situ 
Tumor 2 cm or less in greatest dimension 
Tumor more than 2 cm but not more than 4 cm in greatest 
dimension 
Tumor more than 4 cm in greatest dimension 
Moderately advanced local disease; tumor invasion into the 
mandibular bone marrow, invasion into the submandibular 
space and invasion into the extrinsic muscles of the tongue 
Very advanced local disease; tumor invasion into the 
masticator space, invasion into the pterygoid plate, invasion 
into the skull base, and invasion circumferentially 
surrounding the internal carotid artery 
 
 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension 
Metastasis as specified in N2a, 2b, 2c below 
Metastasis in a single ipsilateral lymph node, more than 3 cm 
but not more than 6 cm in greatest dimension 
Metastasis in multiple ipsilateral lymph nodes, none more 
than 6 cm in greatest dimension 
Metastasis in bilateral or contralateral lymph nodes, none 
more than 6 cm in greatest dimension 
Metastasis in a lymph node more than 6 cm in greatest 
dimension 
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  MX 
  M0 
  M1 
Stage Grouping 
  Stage 0 
  Stage I 
  Stage II 
  Stage III 
 
  Stage IVA 
 
  Stage IVB 
 
  Stage IVC 
Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis present 
 
Tis, N0, M0 
T1, N0, M0 
T2, N0, M0 
T3, N0, M0 
T1-3, N1, M0 
T4a, N0-1, M0 
T1-4a, N2, M0 
Any T, N3, M0 
T4a, any N, M0 
Any T, any N, M1 
Table 1. TNM staging system of OTSCC tumors. (Modified from Kirita & Omura, 2015; 
Compton et al., 2012)  
Since TNM staging system was established in 1950s, it has been universally accepted 
and used in many kinds of solid tumors to give a clear staging evaluation of clinical 
cases. Nevertheless, its guidance on prognosis determination might not be 
informative enough. Other factors are being taken into account in order to facilitate 
the prognostic predication. 
In terms of OTSCC, these factors include tumor proximity to midline, tongue base 
involvement, and other pathological parameters like invasion depth and so on 
(Sahin et al., 2016). 
1.1.2.2. Invasion pattern and depth of OTSCC 
As for the clinical types of OTSCC, there are superficial, exophytic and endophytic 
type which describe different growth patterns of the primary tumor (Fig.1).  
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Fig.1 Clinical types of OTSCC. (a) Superficial type. (b) Exophytic type. (c) Endophytic type. 
(Taken from Kirita & Omura, 2015) 
A previous study analyzed 2,224 tongue cancer patients with T1-2 tumors and saw 
significant differences in prognostic parameters like local recurrence rate, lymph 
node metastasis, distant metastasis, and 5-year survival rate among the three types, 
which showed the potential use of clinical types as a prognostic indicator. OTSCC of 
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endophytic type have higher rate of local recurrence, lymph node and distant 
metastasis, and lower 5-year survival rate than the other two types (Japan Society 
for Oral Tumors, 2005). 
In their invasive front, OTSCC cells can expand with a pushing border, a finger-like 
pattern or some small cell islands (Ahmed Haji Omar, 2015). Worst pattern of 
invasion (WPOI), namely whether cohesive pattern (pushing border, finger-like 
pattern, big cell islands) or invasive pattern (small cell islands, tumor satellites), is 
strongly predictive for prognosis. OTSCC with an invasive pattern WPOI is found to 
be more likely to cause local recurrence and cancer death (Almangush et al., 2015; 
Almangush et al., 2014). 
 
Fig.2 (a) Ultrasonographic image of normal tongue. (b) Measurement of tumor depth. 
(Modified from Kirita & Omura, 2015) 
Besides, invasion depth is another factor associated with OTSCC prognosis. Studies 
showed significantly more frequent local recurrence and cervical lymph node 
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metastasis in early OTSCC tumors with deeper invasion (≥4 mm) (Sahin et al., 2016; 
Almangush et al., 2015). 
Under ultrasonography scanning, the lateral border of the oral tongue (the most 
common site of OTSCC) shows three heterogeneous layers from outmost to inside: 
surface layer, mucosal layer, submucosal and muscular layer (Fig.2a). Tongue 
cancer invasion depth should be measured from the assumed normal mucosal 
surface to the deepest anatomical location, rather than the tumor thickness, since 
swelling and invagination may exist (Fig.2b). 
1.1.2.3 Biology of metastasis 
Over 90% of cancer deaths are caused by distant metastasis other than the primary 
tumors. Metastasis means cancer spreading from the primary tumor to another 
organ. It has several steps: cancer (carcinoma) cells invade through the basement 
membrane reaching nearby stroma from the epithelium, intravasate into lymphatic 
or blood vessels, travel to regional lymph nodes or distant anatomical sites, 
extravasate and eventually colonize there, forming a macroscopic metastasis (Spano 
et al., 2012).  
To get motile and invasive, carcinoma cells need to undergo an epithelial-
mesenchymal transition (EMT), by which their morphology, motility, invasive 
ability and gene expression profile change. Expression of characteristic epithelial 
cell proteins, such as E-cadherin, is suppressed, while production of matrix 
metalloproteinases (MMPs) and proteins only made by mesenchymal cells like 
fibronectin are upregulated (Weinberg, 2013; Irani et al., 2014). Thus cell-cell 
adhesion is lost and the extracellular matrix (ECM) is degraded, which facilitates the 
carcinoma invasion. 
Once normal epithelial cells are detached from the ECM, anoikis, a special form of 
apoptosis is triggered. This process prevents re-adhesion to ectopic locations and 
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uncontrolled proliferation of suspending cells. However, invasive carcinoma cells 
survive from anoikis program and benefit from this disparity (Paoli et al., 2013). 
Even before carcinoma cells break through the basement membrane, they start to 
secret angiogenic factors to stimulate angiogenesis in the stromal part (Weinberg, 
2013). With the overexpressed vascular endothelial growth factors (VEGFs), cancer 
cells attract excess capillaries and get access to the vessels. After the intravasation, 
the disseminated cancer cells travel inside the blood and lymph circulation. During 
the travelling, these cells have to escape from immune surveillance in order to finally 
find a new target tissue to colonize in. 
1.1.2.4. Tongue cancer metastasis 
Tongue cancer metastasizes relatively early. Over 30% patients are with at least one 
enlarged lymph nodes when they first come to have a clinical check (Kirita & Omura, 
2015). Compared with blood vessels, OTSCC is more metastasized via lymphatic 
vessels to regional lymph nodes (Sano & Myers, 2007). Cervical lymph nodes are 
located at seven levels divided by the anatomic regions (Table 2, Fig.3). 
Level IA Submental lymph nodes 
Level IB Submandibular lymph nodes 
Level IIA Superior deep cervical lymph nodes (anterior) 
Level IIB Superior deep cervical lymph nodes (posterior) 
Level III Middle deep cervical lymph nodes 
Level IV Inferior deep cervical lymph nodes 
Level VA Spinal accessory lymph nodes 
Level VB Supraclavicular lymph nodes 
Level VI Pre-laryngeal, pre-tracheal, and para-tracheal lymph nodes 
Level VII Superior mediastinal lymph nodes 
Table 2. Classification of cervical lymph nodes. (Modified from Kirita & Omura, 2015; Sano 
& Myers, 2007) 
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The lymphatic vessels in the tongue compose a dense network. In different areas of 
the tongue, lymphatic fluid flows in various drainage patterns (Werner et al., 2003). 
There are basically three main lymphatic drainage pathways which lead to sentinel 
lymph nodes (SLNs) at different levels in the neck region. The anterior part of the 
tongue has SLNs principally at level I and II. SLNs of the lateral one-third of the 
dorsum of the tongue are mainly at levels I, II, or III. The central pathway drains to 
levels I and III from the central part of the tongue (Sano & Myers, 2007; Han et al., 
2005). Lymph nodes at level I and II receive most of the lymph from the oral tongue. 
And most OTSCC primary lymph node metastases occur at levels I, II, and III (Sano 
& Myers, 2007). 
 
Fig.3 Levels of cervical lymph nodes. (Taken from Carolyn et al., 2012) 
The presence, level and number of nodal metastases are powerful prognostic factors 
of OTSCC. According to Spiro et al. (1986) and Grandi et al. (1985), 2-year survival 
rate of primary OTSCC patient decreases from over 85% to about 50% when cervical 
modal metastasis is found, and 5-year survival rate from 65% to 29%. Furthermore, 
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an extracapsular spread (ECS) means worse prognosis. ECS happens when the 
cancer cells penetrate the metastasized lymph node and are disseminated to the 
neighboring connective tissue. ECS represents higher probability of regional 
recurrence and distant metastasis, which cause most treatment failures of OTSCC. 
In a retrospective study, OTSCC patients with ECS had lower 5-year overall and 
disease-specific survival (DSS) rates than those with nodal metastasis but without 
ECS (Myers et al., 2001). 
Distant metastases of OSCC are rather uncommon compared with other cancers 
(Irani, 2016). The incidence of distant metastasis is associated with the stage and 
location of the primary tumor and the presence of nodal metastasis (Ferlito et al., 
2001). The gingiva is among the most highly metastatic parts in oral cavity along 
with the tongue and the floor of the mouth (Irani, 2016; Osaki et al., 2000). In a 
retrospective study on 332 OTSCC patients treated at Washington University School 
of Medicine, 9.6% of the patients developed distant metastasis, while 21% had 
second primary cancers (Sessions et al., 2002).  
The most common organ of distant metastasis from head and neck region is the 
lungs, followed by the bone, heart and liver (Irani, 2016).  Other less frequently seen 
sites include the brain and the skin (Probert et al., 1974). The mechanism of this 
tissue specificity of metastasis remains unclear. Several theories have been 
proposed to debate on how the metastatic cancer cells are directed to their 
metastasis sites. In 1889, Paget first proposed the concepts of ‘seed’ and ‘soil’, 
standing for metastatic cancer cells and metastasis site respectively. According to 
‘seed and soil’ theory, the location and histopathological property of the primary 
tumor is the determining factors of metastasis pattern. Another theory suggests that 
the C-C chemokine receptors (CCRs) of cancer cells help them to anchor and invade 
into the defined niches where the corresponding chemokines are expressed (Ben-
Baruch, 2009). There are also new theories that emphasize the effects of both 
primary and metastasis sites, and describe metastasis as a multidirectional process 
(Comen et al., 2011). 
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1.1.3. Treatment modalities of OTSCC 
There are various treatment modalities of OTSCC: surgery (local resection, elective 
neck dissection, etc.), radiotherapy, chemotherapy and other composite therapies. 
The treatment plan for an OTSCC patient depends very much on his or her disease 
situation: the location, size and extension of the tumor, and the presence of lymph 
node metastasis.  
It’s very important for local resection surgery to diagnose the invasive range of the 
malignant tumor accurately enough to leave a clear and wide resection margin. 
Previous studies show patients with clear margins had significantly higher 5-year 
DSS rate and were less likely to develop local recurrence (Sessions et al., 2002; Al-
rajhi et al., 2000). 
Radiotherapy is as curative as surgical resection regarding early stage cancer. 
Meanwhile, post-operative radiotherapy is recommended for late stage patients 
with close or positive resection margins, more than one nodal metastases and 
advanced invasion (Kirita & Omura, 2015). For those patients whose bodies cannot 
take an operation, radiotherapy or composite chemoradiotherapy is the prime 
treatment.  
In the retrospective study done on 332 OTSCC patients treated during 1957 to 1996, 
researchers found no significant increase of 5-year DSS within a clinical stage by any 
certain treatment modalities. The 5-year DSS over the whole study was 57.3% 
(Sessions et al., 2002). Another study in Finland investigated the outcome of 
treatment modalities of OTSCC from 1995 to 1999 and from 2005 to 2009, and 
found the 5-year recurrence-free survival rate improved from 47% to 65%, which 
may be attributed to the use of combination treatment of chemoradiotherapy and 
surgery (Mroueh et al., 2017). 
Despite of remarkable improvement of treatment modalities nowadays, the survival 
rate of OTSCC is still unsatisfyingly less than 60%, probably because of the late 
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(stage III and IV) diagnosis of the disease (Rivera, 2014; Bell et al., 2007; Mehrotra 
& Gupta, 2011).  
1.1.4. Shortage of prognostic biomarkers of OTSCC 
Unlike in several other malignancies, there are so far no specific OSCC biomarkers 
in clinical use (Rivera, 2014). Nonetheless, recent researches brought us hope with 
some promising predictive and prognostic biomarkers. For instance, circulating 
miRNAs in blood, serum and plasma show potential to predict OSCC recurrence and 
metastasis (Troiano et al., 2016). Additionally, as a study reported, a loss-of-
heterozygosity status of chromosomes 3p and 9p could be predictive for oral 
premalignant lesions (Zhang et al., 2012). On the other hand, biomarkers found in 
saliva are of great interest due to its direct contact with OSCC lesions (Radhika et al., 
2016). Pro-inflammatory cytokines in saliva such as interleukin-1α (IL-1α), IL-6, IL-
8, tumor necrosis factor-α (TNF-α) and VEGF-α were suggested as proangiogenic 
biomarkers for OTSCC screening (Korostoff et al., 2011). After all, the prognostic 
value of these potential biomarkers on the progression of OTSCC still need further 
investigation (Zheng et al., 2010). 
1.2. Link between inflammation and OTSCC 
1.2.1. Tumor microenvironment 
By the end of last century, more and more researchers realized that cancer 
progression is not only controlled by intrinsic genetic changes of cancer cells, but 
also by a dynamic dialogue between cancer cells and its neighbors (Weinberg, 2013). 
Tumor microenvironment (TME), composed of all the non-neoplastic cells present 
in the solid tumor and the proteins produced by them, in many ways contributes to 
cancer growth, invasion and metastasis (Casey et al., 2015). These non-neoplastic 
cells include immune cells, fibroblasts and many other cells (Pottier et al., 2015). As 
an essential part of TME, immune cells play a dual role as anti-tumorigenesis 
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guardians and pro-tumorigenesis accomplices, depending on which immune 
mechanism is triggered. 
1.2.2. Cancer-related inflammation 
1.2.2.1. ‘Good’ and ‘bad’ inflammation in cancer 
Since 1863 when Rudolph Virchow first suggested the potential relationship 
between cancer and inflammation with the presence of leukocytes in neoplasm, 
there has been a good amount of evidence to validate his hypothesis.  
Cancer has many similar properties to wound healing. Malignant cells are like 
invading parasites that rely on the host (stroma) to provide them with nutrients, 
oxygen and room to proliferate. The supply is done through abundantly vascularized 
connective tissue stroma, which is induced by VEGF, the growth factor both cancer 
cells and macrophages secrete. The active cellular inflammation components in 
wound healing, namely neutrophils, macrophages and lymphocytes, are also 
common in TME (Dvorak, 2015). Together with mediators they release, the 
recruited inflammatory cells composite an immunological environment, or so-called 
‘smoldering’ inflammation that favors cancer cells’ proliferation, metastasis, 
escaping from immune response, and angiogenesis (Mantovani et al., 2008). In that 
sense, cancer resembles a persistent infection in wound that continuously fails to 
heal (Dvorak, 2015). 
Different inflammatory cells in TME have different effects on tumorigenesis. 
Generally they can be divided into two groups: ‘good’ inflammatory cells that kill 
cancer cells and evoke anti-tumorigenic immune responses, and ‘bad’ ones that 
harbor both immunosuppression and pro-tumorigenic activities (Shiao et al., 2011). 
CD4+ T lymphocytes 
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Adaptive immune response is the major part of cancer recognition and rejection, 
involving antigen presenting cells (APCs), T and B lymphocytes, cytokines and major 
histocompatibility complex (MHC) system. MHC system is the cell surface proteins 
that help binding peptide antigen of pathogens and present them on cell surface in 
order to be recognized by T cells (Janeway et al., 2001). MHC are classified to class I 
(with β2 subunits) and II (without β2 subunits). Most cancer cells are positive for 
MHC I, which is only targeted by CD8+ T cells to induce direct cancer cell killing 
(Pardoll & Topalian, 1998). On the other hand, CD4+ T cells specifically recognize 
MHC class II molecules. That’s why CD8+ T cells have been considered the major 
component in adaptive immunity against cancer for quite a long time. However, 
from 1994 and on, researchers have demonstrated more and more tumor antigens 
recognition by CD4+ T cells, suggesting induction of CD4+ T cells by tumor is also an 
indispensable arm of antitumor adaptive immunity (Topalian et al., 1994). 
CD4+ T cells are central mediators in immune system. They regulate, aid and balance 
other immune cells’ activities, like antibody production by B cells, cytotoxic activity 
of CD8+ T cells and functions of macrophages. They also suppress immune response 
to regulate autoimmunity and control the response shutdown (Zhu et al., 2009). As 
for cancer immunity, tumor infiltrating CD4+ T cells subsets have complicated effects 
on the immune response to cancer cells. 
Upon recognition of MHC class II molecules presented by APCs, CD4+ T cells are 
activated and differentiated into subsets controlled by different cytokines induction. 
These subsets include T helper 1 (Th1), Th2, T regulatory (Treg), Th17, Th22 and 
follicular T helper (Tfh) (Protti et al., 2014). The correlation between cancer and Th1, 
Th2 and Treg is the most discovered and characterized. 
Induced by IL-12 and IFN-γ, naïve CD4+ T cells differentiate to Th1 cells, and 
characteristically secrete TNF-α and IFN-γ. Th2 differentiation is induced by IL-4 
and thymic stromal lymphopoietin. IL-4, IL-5 and IL-13 are cytokines production of 
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Th2 cells. Treg cells differentiate by TGF-β, and release TGF-β and IL-10 (Zhu et al., 
2009). 
Higher concentration of tumor infiltrating Th1 cells and its production of cytokines 
are strongly related with better prognosis of cancers. In contrast, Th2 and its 
products including immunosuppressive cytokine IL-10, are associated with tumor 
progression, with a few exceptions (Fridman et al., 2012). Treg cells infiltration into 
a tumor suppresses antitumor immune response and also corresponds to poor 
prognosis in many cancers (Takeuchi & Nishikawa, 2016). 
CD8+ T cells and NK cells 
Naïve CD8+ T cells are activated to cytotoxic T lymphocytes (CTLs) by tumor-
associated antigen co-presented with MHC class I molecules by APCs. CTLs target 
cancer cells by interaction between T cell receptor and antigenic peptide on the 
surface of cancer cell, and release cytotoxic granules that contain granzymes in 
order to break down proteins inside cancer cells and induce apoptosis. CTLs also 
target cancer cells by Fas/Fas ligand (Fasl) interactions, which activate the pathway 
of caspase cascade, resulting in apoptosis of cancer cells as well (Ruddon, 2007). 
NK cells are stimulated by cytokines like IFN-γ, secreted by both T cells and 
activated NK cells. Cytotoxicity of NK cells doesn’t rely on MHC antigen expression 
(Trinchieri, 1989). NK cells receptors sense activating or inhibitory signals by 
interaction with cancer cells ligands, thus targeting cancer cells that have reduced 
ligands to trigger inhibitory signals and increased ligands for activation signals (Pahl 
& Cerwenka, 2017). Like CD8+ T cells, NK cells kill cancer cells by releasing cytotoxic 
granules and Fas/Fasl interacttions (Smyth et al., 2005). 
Macrophages: M1 or M2? 
Macrophages are the most abundant immune cells infiltrating in TME. Tumor 
associated macrophages (TAMs) have shown promoting effects on cancer 
16 
 
progression in most of the cases (Qian & Pollard, 2010). The high density of 
macrophages in tumor is correlating with poor prognosis of a number of cancers 
(Bingle et al., 2002). Macrophages can be recruited and regulated by tumor cells via 
secretion of cytokines such as VEGF, platelet-derived growth factor (PDGF), C-C 
chemokine ligands (CCL)-2, TGF-β and TNF-α (Mantovani & Sica, 2010). Local TAMs 
support tumor-associated angiogenesis, promote invasion and migration of cancer 
cells, and suppress immune response against tumor.  
Although considerable amount of clinical and experimental evidences show that 
TAMs are in favor of malignancy, there are exceptions. For example, in a rat model, 
liver macrophages killed circulating cancer cells and inhibited metastasis (Heuff et 
al., 1993). Accumulating research results suggest that macrophages play 
multifaceted roles in the progress of malignancy. As in wound healing, TAMs are 
dynamically activated and differentiate into M1 or M2 phenotypes according to the 
signals in TME.  
M1 phenotypic TAMs differentiation relies on cytokines like IFN-γ and TNF-α. The 
product of M1 TAMs include nitric oxide species, and pro-inflammatory mediators 
such as IL-12, IL-6 and TNF-α. They have tumouricidal properties and elicit tissue 
destruction (Mantovani & Sica, 2010). Nonetheless, the phenotype of TAMs that 
prevails in most cancer TME is M2. It is thought that cancer cells switch TAMs 
phenotypes from M1 to M2 through production of IL-10, colony stimulating factor 
(CSF)-1, CCL2, etc. (Mantovani & Sica, 2010; Roca et al., 2009). M2 phenotypic TAMs 
produce VEGF, MMPs, epidermal growth factor (EGF), which promote tumor growth, 
angiogenesis, invasion and migration (Qian & Pollard, 2010). Additionally, M2 TAMs 
suppress anti-tumor adaptive immune activities (cytotoxic T cell responses) and 
recruit Treg cells by CCL22 (Biswas & Mantovani, 2010), keeping an immune 
ecosystem that favors tumor progression. 
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1.2.2.2. Chemotaxis effect of cancer cells to attract inflammatory cells 
Chemotaxis is the polarized movement of cells directed by the concentration 
gradient of an extracellular chemokine. In cancer, chemotaxis is involved in both 
cancer cells dissemination and TME shaping. This process is mediated by various 
chemokines (or growth factors) and chemokine receptors (or growth factor 
receptors) (Roussos et al., 2011),  
Along with other stromal cells, cancer cells secret chemokines to recruit 
inflammatory cells which express the corresponding chemokine receptors. For 
instance, Treg cells expressing CCR4 are attracted by CCL22, a chemokine ligand 
secreted by ovarian cancer cells and TAMs (Curiel et al., 2004). Besides, in breast 
cancer, tumor-derived CCL2 and CCL5 attract T cells and other immune cells 
carrying CCR1 such as monocyte precursor cells, to accumulate in TME and suppress 
anti-tumor immune response (Soria & Ben-Baruch, 2008). On the other hand, 
colorectal cancer cells secret C-X-C chemokine ligand 16 (CXCL16) and attract 
cytotoxic effector cells such as CD8+ and CD4+ T cells with C-X-C chemokine receptor 
6 (CXCR6), leading to a good prognosis (Koizumi et al., 2007). 
In general, via chemotaxis of certain inflammatory cells, cancer cells establish a TME 
of particular design, which may have conflicting effects on immune evasion of cancer, 
depending on type of the infiltrating cells. 
1.2.2.3. Inflammatory infiltrations and prognosis of OTSCC 
Oral tongue tumors have more intense inflammatory response than tumors of the 
whole head and neck region (Lundqvist et al., 2012). Previous study showed that 
human oral cancer infiltrating lymphocytes injected into nude mice with 
transplanted human tongue squamous cell carcinoma cell lines Tca 8113 strongly 
inhibited the transplanted tumor growth (Liao et al., 1998).  Further research found 
that dense lymphocytic infiltration correlated with better radiotherapy response 
and fewer recurrences in OTSCC (Lundqvist et al., 2012). These in vivo experimental 
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results and clinical facts suggest a positive effect of inflammatory infiltrations on 
prognosis of OTSCC. 
Despite the overall positive impact, a study focusing on specific pro-tumorigenic 
components of inflammatory infiltrations in TME of OTSCC revealed that denser 
infiltrations of Treg cells (Foxp3+), M2 phenotypic TAMs (CD163+) and Treg-
inducing immune cells (CD80+) were associated with higher locoregional 
recurrence. The recurrence hazard ratio of OTSCC with a high density of 
CD163+Foxp3+CD80+ infiltrations versus low density was 2.9 (Dayan et al., 2012).  
The presence of TAMs plays a role in promotion of OSCC cells invasion and 
angiogenesis (Li et al., 2002). It is a predictor of poor prognosis of oral cavity cancers 
(Marcus et al., 2004). A significant correlation between TME rich in CD163+ TAMs 
and poor outcome of OSCC has been seen in an investigation including 108 OSCC 
patients (Fujii et al., 2012). More specifically, in vitro experiments with horizontal 
and 3D models showed M2 TAMs induced migration and invasion of OTSCC cells 
(HSC-3 cell line) and affected cytokine production of cancer cells in favor of tumor 
progression. But in the same experiments, M1 TAMs had a negative effect on OTSCC 
cells invasion (Pirilä et al., 2015). 
The research results mentioned above suggest the necessity of looking at specific 
subsets of inflammatory infiltrations in OTSCC when investigating their impact on 
cancer progression.  
1.2.3. Cancer cell extracellular vesicles  
Extracellular vesicles (EVs) can be released to extracellular space by many cell types, 
with size from 40 to 200 nm. They originate from multivesicular endosomes that 
fuse with the plasma membrane (Raposo & Stoorvogel, 2013). EVs can contain 
proteins, lipids, RNA and DNA. They are found in diverse body fluids, including blood, 
urine, saliva, breast milk, and also conditioned cell culture media (van der Pol et al., 
2012). Their function was earlier thought to be removal of excess cellular 
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constituents and recycling cell surface proteins in case to regulate outside-in 
signaling (Pan et al., 1985). What’s more, EVs deliver their contents to distant 
recipient cells by fusion with them, likely to mediate the recipient cells phenotypes, 
which indicates the role of EVs as mediators in cell-to-cell communication without 
direct interactions (De Toro et al., 2015). 
Interestingly, blood of cancer patients contains approximately 2-fold more EVs than 
normal, and cancerous cells secret even more EVs, which is suspected to be due to a 
change of cellular physiology (Kalluri, 2016). Lots of in vitro and in vivo studies 
demonstrated the potential modulating effects of cancer-derived EVs on 
tumorigenesis, angiogenesis, fibroblasts activation, immune suppression, and even 
metastasis pre-niche formation (Beckler et al., 2013; Fernandes Ribeiro et al., 2013; 
Webber et al., 2015; Clayton et al., 2007; Costa-Silva et al., 2015).  
1.2.3.1. Suppression of immune surveillance by cancer-derived EVs 
Cancer-derived EVs can impair the maturation of APCs and inhibit anti-tumor 
immune responses. EVs of mammary cancel cells are able to induce myeloid 
precursor cells in the bone marrow to produce IL-6, which promotes blocking their 
differentiation into dendritic cells in vitro (Yu et al., 2007). EVs derived from human 
melanoma also impair differentiation of CD14+ monocytes into dendritic cells and 
even promote generation of a myeloid immunosuppressive cell subset (Valenti et al., 
2006). 
In mice model, cancer EVs decrease cytotoxicity and proliferation of both T cells and 
NK cells, benefiting tumor progression (Zhang & Grizzle, 2011). Many cancers have 
EVs that trigger the generation of extracellular adenosine, which suppresses T cell-
mediated immune regulation (Clayton et al., 2011). In vitro experiment of EVs from 
diverse cancer cell lines showed that they downregulated expression of NKG2D, an 
activating receptor for cytotoxic inflammatory cells like NK cells and CD8+ T cells 
(Clayton et al., 2008). Cancer EVs carrying Fasl can exert Fas-dependent apoptosis 
of Fas+ T cells (Andreola et al., 2002). Besides, cancer EVs promote Treg cells 
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expansion, and enhance their immune suppressing function and resistance against 
apoptosis, which are mediated by TGF-β1 and IL-10 (Clayton et al., 2007; Szajnik et 
al., 2010).  
Macrophages polarization can also be affected by cancer EVs. After exposure to EVs 
derived from glioblastoma multiforme, monocytes were expressing significantly 
higher CD163, the M2 phenotypic marker (de Vrij et al., 2015). 
1.2.3.2. Stimulation of immune response by cancer-derived EVs 
As EVs contain proteins, nucleic acids and membrane-derived lipids from parental 
cells, they somewhat carry characteristic information of these cells. In fact, cancer 
EVs can bear cancer associated antigens with them, thus being potentially capable 
to be used as an anti-tumor vaccine (Kunigelis & Graner, 2015). For example, an in 
vitro model showed that EVs derived from many human cancer cell lines transferred 
cancer associated antigens to dendritic cells. In the same study, upon the taking of 
EVs antigens, mouse dendritic cells induced potent CD8+ T cell-dependent anti-
tumor immune response (Wolfers et al., 2001). Heat shock protein 70-positive 
cancer EVs can also stimulate the migration and cytolytic activity of NK cells 
(Gastpar et al., 2005).  
Although preclinical experiments done in animal models show upregulated anti-
tumor immunogenicity by cancer EVs, the reported immune activities of cancer EVs 
indicate their overwhelming effect of immunosuppression in clinical trial and other 
experiments. The dichotomy of cancer EVs effects on cancer immunity remains to 
be investigated. More attention is supposed to be paid to the context where EVs are 
located and antigens are presented, which might explain the functional 
heterogeneity of cancer EVs (Kunigelis & Graner, 2015). 
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2. Aims of the study 
This study aims to investigate the interaction between OTSCC cells and 
inflammatory cells and answer 3 questions: 
1. How inflammatory cells affect OTSCC cells’ activities such as proliferation, 
migration and invasion? 
2. How EVs of OTSCC cells affect macrophages polarization? 
3. How EVs of OTSCC cells affect cytotoxic activity of CD8+ T cells and NK cells? 
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3. Materials and methods 
3.1. Peripheral blood mononuclear cells isolation 
Human buffy coat of three healthy donors was provided by Finnish Red Cross. We 
used Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ, USA), a density gradient 
medium to isolate human peripheral blood mononuclear cells (MNCs).  
To isolate cytotoxic CD8+ T cells, CD56+ NK cells and CD14+ monocytes from the 
MNCs, we used a MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany) with 
a negative selection. MNCs were resuspended in a buffer of PBS, BSA and EDTA to 
get a concentration of 107 cells in 40 µl. We added 10 µL of biotin-antibody cocktail 
and incubated the cells for 5 minutes at 4°C. After that, 30 µl of the buffer was added 
followed by 20 µl of the cell microbeads cocktail. The mixture was incubated for 10 
minutes at 4°C and then it was loaded in the LS Column in the magnetic field. 
Unlabeled cells which passed through the column were collected.  
A panel of antibodies (BD Biosciences, San Jose, CA, USA) were used to further check 
the purity of the isolated cells. The panel included anti-CD3-APC (T cells common 
antigen), anti-CD8-PerCP-Cy5.5 (CD8+ T cells), anti-CD14-FITC (monocytes) and 
anti-CD56-PE (NK cells). The different cell populations were stained with antibodies 
of the panel, and acquired by FACS-Verse, and then analyzed by BD FACSuite™ 
software. 
The percentage of CD3+ CD8+ T cells, CD3- CD14+ monocytes, and CD3- CD56+ NK 
cells in the isolated population were 96%, 92% and 92% respectively (Fig.4). 
3.2. Human OTSCC cell culture 
Two OTSCC cell lines were used in this study. HSC-3 cells (Japan Health Sciences 
Foundation, Japan) are highly invasive cells while SCC-25 cells (American Type 
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Culture Collection, Manassas, VA, USA) are poorly invasive. The difference in the 
invasive properties of these cell lines was reported by Ramos et al. (1997).  
 
Fig.4 Inflammatory cells purity test with FACS. Isolated inflammatory cells were stained 
with anti-CD3-APC, anti-CD8-PerCP-Cy5.5, anti-CD14-FITC and anti-CD56-PE; and acquired 
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by FACS-Verse, and then analyzed by BD FACSuite™ software. The diagrams show the 
percentage of CD3+ CD8+ T cells (A), CD3- CD14+ monocytes (B) and CD3- CD56+ NK cells (C). 
The 3 diagrams on the left show percentage of the positive cells after gating. 
The medium used to culture the cell lines was Dulbecco’s modified Eagle’s medium 
(DMEM)-12 (Gibco, Paisley, UK) along with 10% heat-inactivated fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml fungizone, and 50 
μg/ml ascorbic acid. The cells were cultured in 75 cm2 flasks at 37∘C in 5% CO2 
incubator. 
3.3. Co-culture of human OTSCC cells and human peripheral blood MNCs in an 
organotypic 3D myoma model 
We developed a 3D in vitro organotypic model using human uterine leiomyoma 
discs to study the effects of human peripheral blood MNCs on proliferation and 
invasion of OTSCC cells, and the chemotaxis ability of cancer cells to attract MNCs. 
The myomas were taken from the by-product of routine surgical operations after 
getting the informed consent from the donors at the Oulu University Hospital, 
Department of Gynecology. The use of the myoma tissue was approved by the Ethics 
Committee of the Oulu University Hospital. 
In a previous study, the myoma in vitro invasion model has been well established 
(Nurmenniemi et al., 2009). With some adjustment, we followed the described 
instructions to prepare the myomas and conduct the invasion experiments.  
The uterine leiomyoma tissue was cut into macroscopically homogeneous discs 
which were 2 mm-thick and 8 mm in diameter. The discs were placed into the 
bottom of Transwell® inserts (Corning Inc., Corning, NY, USA). 5x105 HSC-3 or SCC-
25 cells were added on top of each myoma disc (Day 0). After overnight incubation 
(37∘C, 5% CO2) to let the cells attach to myoma, the discs were removed from the 
Transwell® inserts and transferred onto steel grids placed in 12-well plate (Day 1). 
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Each well was beforehand filled with 1.2 ml culture medium to reach the 
undersurface of myoma discs and the medium was replaced every three days. 
On Day 4, 2x106 MNCs were added in the medium beneath the myoma discs either 
alone (Group 2, non-activated) or with different activators. To stimulate T cells, 
MNCs were added in medium with 2 µg/ml CD28 antibody (BD Bioscience) in wells 
coated with 5 µg/ml CD3 antibody (BD Bioscience, Group 3). To activate all MNCs, 
the medium beneath contained 5 ng/ml phorbol 12-myristate 13-acetate (PMA, 
Sigma Aldrich, St. Louis, Mo, USA) and 1 µM ionomycin (BD Bioscience, Group 4). For 
control without MNCs, we had medium alone (Group 1) and medium with 5 ng/ml 
PMA and 1 µM ionomycin (Group 5) beneath the myoma discs. The co-culture lasted 
until Day 10. 
The myoma model set of the invasion experiment is demonstrated in Fig.5. 
 
Fig.5 Organotypic 3D myoma co-culture model of OTSCC cells and human peripheral 
blood MNCs. 5x105 HSC-3 or SCC-25 cells were added on top of each myoma disc. After 24-
hour adhesion, the myoma discs were transferred onto metal grids placed in wells of 12-
well plates. The wells were beforehand supplied with 1.2 ml medium. On the 4th day of the 
whole 10-day experiment, 2x106 MNCs were added beneath the discs with or without 
activators (CD3 and CD28 antibodies, or PMA and ionomycin). 
3.4. Immunohistochemical (IHC) staining of myoma 
After the co-culture, myoma discs were fixed in 10% formalin and embedded in 
paraffin blocks. The discs were then vertically cut into 6 µm-thick sections using a 
microtome. The slides were stained with a horseradish peroxidase–labeled dextran 
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polymer method using Leica BOND-MAX staining robot (Leica Microsystems, 
Wetzlar, Germany). The primary antibodies used here were monoclonal mouse anti-
human pan-cytokeratin (0.7 µg/ml), monoclonal mouse anti-human Ki67 (0.8 
µg/ml), monoclonal mouse anti-human CD45 (0.94 µg/ml), and monoclonal mouse 
anti-human CD8 (3 μg/ml; all from DAKO, Glostrup, Denmark). 
3.5. Scratch wound OTSCC cell migration assay 
Wells of a 96-well Imagelock plate (Essen Bioscience, Ann Arbor, MI, USA) were 
coated with 300 µg/ml Myogel, a cell culturing matrix formulated from human 
myoma tissue in order to substitute Matrigel® derived from mouse (Salo et al., 2015). 
After overnight incubation (37∘C, 5% CO2), excess myogel was removed and 3x104 
HSC-3 or SCC-25 cells were seeded to each well. The cells were left to adhere 
overnight. 
Identical scratch wounds of 700-micron width were made in all wells using a 
WoundMaker™ (Essen Bioscience). Wells were washed with PBS and the medium 
was replaced by 100 µl of fresh medium with 8x104 MNCs either alone or with 
activators (as in the invasion experiment). For control without MNCs, we replaced 
the medium with fresh medium only, and medium with 5 ng/ml PMA and 1 µM 
ionomycin. 
The wound healing process in each well was monitored by an IncuCyte Live-Cell 
Imaging System (Essen Bioscience), and pictures were taken every an hour to 
measure the wound area over time. 
3.6. EVs isolation and characterization 
We seeded 1.3x106 HSC-3 or SCC-25 cells per 75 cm2 flask and left them to adhere 
overnight. We discarded the medium and washed the flasks with PBS, followed by 
adding serum-free DMEM-12 medium. After another 48-hour culturing, we 
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centrifuged the medium at 1000 rpm for 5 min, and collected the supernatant for 
EVs isolation. 
We conducted a two-step ultracentrifugation (Beckman Coulter, Pasadena, CA, USA) 
to isolate EVs out of the medium. In the first step, the medium was centrifuged at 10 
000 g for 1.5 hours at 4°C. Then the supernatant was collected and further 
centrifuged at 100 000 g for 1.5 hours at 4°C. After the second ultracentrifugation, 
we discarded the supernatant, re-suspended the EV-containing pellet with 200µl of 
PBS and kept it at -80°C for further use. 
After EV isolation, the number and size of the particles were measured using 
nanoparticle tracking analysis (NTA). A Nanosight model LM14 (Nanosight) 
equipped with a blue laser (404 nm, 70 mW) and a SCMOS camera was used. We 
diluted the samples in DPBS and recorded three 90-second videos by camera level 
14. The acquired data was analyzed by NTA software 3.0 with the optimized 
detection threshold and screen gain at 10. 
To check the samples with immune-electron microscopy, we applied EV 
suspensions onto 200-mesh grids and fixed with 2% PFA. After blocking with 0.5% 
BSA in 0.1 M NaPO4 buffer (pH 7.0) for 10 min, samples were stained with 
monoclonal mouse anti-human CD63 primary antibody (Pelicluster, Sanquin, 
Amsterdam, The Netherlands), and then anti-mouse secondary antibodies 
conjugated to colloidal gold particles (10 nm) in 0.1% BSA in 0.1 M NaPO4 buffer (pH 
7.0) for 30-60 min at room temperature. After extensive washing with 2% neutral 
uranyl acetate, the samples were embedded in methyl cellulose uranyl acetate 
mixture (1.8/0.4%). The samples were examine with a Tecnai 12 (FEI Company, 
Eindhoven, The Netherland) operated at 80 kV, equipped with Gatan Orius SC 1000B 
CCD-camera (Gatan Inc. USA) using 4008 x 2672 px image size and no binning. 
According to the characterization outcome, most analyzed EVs were between 50-
100 nm in diameter and CD63+ (Fig.6). 
28 
 
3.7. Monocytes differentiation and macrophage polarization 
As mentioned, human peripheral blood primary monocytes (CD14+) were isolated 
and tested to be 92% purified. The monocytes were seeded in 24-well plates (2x105 
cells per well) and the medium was advance RPMI-1640 (Gibco) supplied with 10% 
FBS, 1% L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml 
fungizone. Monocytes were left to adhere for 1.5 hours and then unattached cells 
were washed away with PBS and fresh medium plus 100 ng/ml macrophage colony 
stimulating factor (M-CSF; R&D systems, Minneapolis, MN, USA) was added. The 
treatment lasted for 7 days to let the monocytes differentiate to macrophages, and 
images of the cells were taken daily with a Nikon DS-Fi2 camera (Nikon, Tokyo, 
Japan). 
 
Fig.6 Characterization of the OTSCC cells EVs with NTA and electron microscope. 
Isolated EVs samples were analyzed by nanoparticle tracking analysis (NTA). To visualize 
their immune characteristic, the EVs were stained with CD63 and observed with electron 
microscope. Most analyzed EVs were between 50-100 nm in diameter for both HSC-3 (A) 
and SCC-25 (B), and CD63+ (pointed by arrow) for HSC-3 (C) and SCC-25 (D). 
To study the effects of OTSCC cells derived EVs on macrophages polarization, the 
differentiated macrophages were then treated with EVs isolated from HSC-3 or SCC-
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25 cells for 24 hours. For positive control, we used 10 ng/ml Lipopolysaccharides 
(LPS, Sigma-Aldrich) and 20 ng/ml IFN-γ (Prospec, Rehovot, Israel) to differentiate 
macrophages to M1 phenotype, and 20 ng/ml IL-4 and 20 ng/ml IL-13 (Prospec) to 
M2 phenotype. Primary macrophages without treatment were set as M0 control. 
3.8. Quantitative real time-PCR 
The total RNA from macrophages was isolated using RNeasy Mini Kit (Qiagen, 
Düsseldorf, Germany). 200 ng of RNA was used for cDNA synthesis with an iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). For each PCR tube, 2 µl of cDNA 
sample along with 10 µl iQ SYBR green, 7 µl water and 1 µl of 250 nM primer solution 
were added. GAPDH and RPLP0 were used as housekeeping genes. Primer 
sequences are shown in Table 3: 
Gene Forward Reverse 
CXCL9 5’-ACCCAGATTCAGCAGATGTGAAGGA-3’ 5’-GCCATCCTCCTTTGGAATGATAGCG-3’ 
CXCL10 5’-GCAAGCCAATTTTGTCCACGTGTTG-3’ 5’-CAGCCTCTGTGTGGTCCATCCTT-3’ 
CCL17 5’-GGACCTGCACACAGAGACTCC-3’ 5’-CCCTTGAAGTACTCCAGGCAGC-3’ 
CCL18 5′-TGGCAGATTCCACAAAAGTTCA-3′ 5′-GGATGACACCTGGCTTGGG-3′ 
CCL22 5’-GTGGCGCTTCAAGCAACTGA-3’ 5’-GGGGCAGACGGTAACGGAC-3’ 
GAPDH 5’-AAGGTCATCCCTGAGCTG-3’ 5’-TGCTGTAGCCAAATTCGTTG-3’ 
RPLP0 5’-GGCGACCTGGAAGTCCAACT-3’ 5’-CCATCAGCACCACAGCCTTC-3’ 
Table 3. Sequences of the primers used in this study. 
3.9. IncuCyte™ immune cell killing assay 
The cytotoxic activity of CD8+ T cells and NK cells against OTSCC cells were 
measured using an IncuCyte™ immune cell killing assay.  
First, we labeled HSC-3 and SCC-25 cells with fluorescent dye using a CellTraceTM 
Far Red Cell Proliferation Kit (Invitrogen, Carlsbad, CA, USA). The OSTCC cells were 
seeded in 96-well plates (5000 cells per well) and left to adhere overnight. CD8+ T 
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cells and NK cells were cultured in either medium alone (control) or medium 
supplied with EVs derived from HSC-3 or SCC-25 for 24 hours. The cytotoxicity 
activators were 100 ng/ml CD3 antibody and 10 ng/ml IL-2 (eBioscience, San Diego, 
CA, USA) for CD8+ T cells, and 10 ng/ml IL-2 for NK cells. 
After the 24-hour culturing, 5x104 CD8+ T cells or NK cells were added to the OTSCC 
cells in the wells supplied with 2.5µM IncuCyte™ Caspase-3/7 Apoptosis Assay 
Reagent (Essen Bioscience). For controls, only corresponding cytotoxicity activators 
were added to cancer cells. Then the cytotoxic activities were monitored using 
IncuCyte Live-Cell Imaging System for 5 days and pictures were taken every two 
hours to measure the apoptosis of OTSCC cells induced by CD8+ T cells and NK cells. 
3.10. Microscopic and histomorphometric analysis 
Stained myoma slides were observed and photographed using Leica DM6000 B/M 
light microscope connected to a digital camera (DFC420; Leica Microsystems). 
Invasion area and depth of OTSCC cells in the myomas were measured using ImageJ 
software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA). 
At 10x magnification, the surface area of immunostained (pan-cytokeratin) invading 
cells into the myomas were measured. The maximal invasion depth (distance from 
the deepest invading cell to the lower surface of the non-invading cell layer) was 
also measured. 
Percentage of Ki67+ OTSCC cells were calculated at 40x magnification from at least 
three randomly selected fields of the non-invading cell layer per slide. Numbers of 
CD45+ and CD8+ cells were counted at 10x or 20x magnification from at least three 
fields showing the most intensive infiltration per slide. 
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3.11. Statistical analysis 
All experiments were done in duplicate or triplicate and repeated for 3 to 8 
independently times. Values are provided as means ± standard deviation. One Way-
Anova followed by Tukey’s post hoc test was used to check statistical significance. P 
values less than 0.05 were regarded as statistically significant. Pearson correlation 
test was used to examine the correlations between the OTSCC cells’ proliferation 
and the invasion area/depth. 
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4. Results 
4.1. Human peripheral blood MNCs’ effects on proliferation, invasion area and 
depth of OTSCC cells in 3D organotypic myoma discs 
After co-culturing OTSCC cells and human peripheral blood MNCs in the myoma 
invasion model, the myomas were cut into 6 µm-thick sections and 
immunohistochemically stained with pan-cytokeratin and Ki67. Staining of pan-
cytokeratin displayed distribution of HSC-3 and SCC-25 cells in the myoma discs. As 
described in previous study, HSC-3 showed more aggressively invasion into the 
myoma tissue than SCC-25 (Fig.7A, B). The percentage of Ki67 positive (proliferative) 
cancer cells in the total non-invading cancer cells (cells on the surface layer, not 
inside myoma) for HSC-3 and SCC-25 cell lines was close to each other (Fig.7D, E). 
For controls, myoma discs without cancer cells were negative for both pan-
cytokeratin and Ki67 (Fig.7C, F). 
The proliferation of both OTSCC cell lines was decreased after adding activated 
MNCs (HSC-3, p=0.04; SCC-25, p=0.03). Interestingly, activated CD3+ T cells only 
lowered the proliferation percentage of SCC-25 (p=0.002, Fig.8A).  
Activated MNCs reduced invasion area of HSC-3 cells (p=0.04), but showed no 
significant effects on invasion area of SCC-25, which had an overall much lower level 
of invasion area compared with HSC-3 (Fig.8B). Invasion depth of both OTSCC cell 
lines were not affected by adding inflammatory cells (Fig.8C). 
For both OTSCC cell lines, proliferation showed positive correlation with the 
invasion area (HSC-3, r=0.5, p=0.002; SCC-25, r=0.5, p=0.02; Fig.8D), but no 
correlation with the invasion depth (HSC-3, r=0.2, p=0.1; SCC-25, r=0.1, p=0.6; 
Fig.8E). 
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Fig.7 Immunohistochemical staining with pan-cytokeratin and Ki67 of myoma 
sections. HSC-3 cells showed more aggressively invasion into the myoma tissue than SCC-
25 (A, B). The percentage of Ki67+ cells was similar for both cell lines (D, E). Myoma discs 
without cancer cells were negative for both pan-cytokeratin and Ki67 (C, F). Scale bar=100 
µm. 
4.2. Migration of peripheral blood MNCs towards OTSCC cells in myoma discs 
The myoma slides were immunohistochemically stained with CD45 (leukocyte 
common antigen) and CD8 (cytotoxic T cells marker) antibodies. Since there were 
some inflammatory cells already present in myoma tissue, we set groups without 
co-cultured MNCs beneath as controls. The myomas used in this experiments were 
all derived from the same batch and macroscopically homogeneous. 
From the stained slides we observed that when activated MNCs were added, CD45+ 
cells were more abundant in myoma (Fig.9A-D). However, this difference was not 
statistically significant (Fig.9I, J).  
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Fig.8 Effects of activated MNCs on proliferation, invasion area and depth of OTSCC 
cells. The percentage of Ki67+ cells in the total non-invading cancer cells was counted from 
at least three randomly selected fields (A). Invasion area and invasion depth were measured 
using ImageJ software (B, C). Correlations between proliferation and invasion area and 
invasion depth were examined using Pearson correlation test (D, E), Statistical significance 
was checked using One Way-Anova followed by Tukey’s post hoc test. *p ≤ 0.05, **p ≤ 0.01. 
All experiments were done in duplicate and repeated for 4 to 8 times independently. 
CD8+ T cells density in myoma was also raised by adding activated MNCs, and they 
were mostly found at the bottom of the myoma and close to blood vessels (Fig.9E-
H). The increase was statistically significant only for HSC-3 cells (p=0.02) which 
were more invasive, but not for SCC-25 (p>0.05, Fig.9K, L). 
By adding inactivated MNCs, we didn’t see migration of  the peripheral blood MNCs 
towards OTSCC cells in myoma (Fig.9E-H). 
4.3. Migration of OTSCC cells on top of Myogel in scratch wound healing assay 
We co-cultured OTSCC cells and peripheral blood MNCs on top of Myogels in 96-well 
plate to study the effects of peripheral blood MNCs on migration of cancer cells. The 
wound closing process over time was recorded (Supplement 1).  
The migration of HSS-3 or SCC-25 wasn’t affected by the presence of peripheral 
blood MNCs. MNCs activated by PMA and ionomycin impeded the wound closing 
process compared with control and other co-culture groups, nevertheless, the 
activators themselves (PMA and ionomycin) also inhibited the migration (Fig.10). 
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Fig.9 Migration of peripheral blood MNCs towards OTSCC cells in myoma discs. Myoma 
slides were stained with CD45 (A-D) and CD8 (E-H). The photos shown here are from 
experiment using HSC-3 cells. Numbers of CD45+ (I, J) and CD8+ cells (K, L) were counted at 
10x or 20x magnification from at least three fields showing the most intensive infiltration 
per slide. Statistical significance was checked using One Way-Anova followed by Tukey’s 
post hoc test. *p ≤ 0.05. Scale bar=100µm. 
4.4. Human primary macrophage polarization in the presence of OTSCC cells EVs 
Human primary monocytes were isolated and treated with M-CSF for 7 days for 
differentiation into macrophages (Fig.11A). Then the macrophages were treated 
with EVs isolated from HSC-3 or SCC-25 cells for 24 hours. For positive control, we 
used LPS and IFN-γ to polarize macrophages to M1 phenotype, and IL-4 and IL-13 
to M2 phenotype. Primary macrophages without treatment were set as M0 control. 
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Fig.10 Peripheral blood MNCs showed no effects on migration of OTSCC cells. Scratch 
wound OTSCC cell migration assay on top of Myogel in 96-well plate was done. Pictures 
taken over time of wound closing process of HSC-3 cells alone (A), and HSC-3 cells with co-
cultured MNCs, PMA and ionomycin (B). Wound closing percentage over time of HSC-3 (C) 
and SCC-25 (D) with or without co-cultured MNCs. 
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Fig.11 OTSCC cells EVs showed no effect on human primary macrophages polarization. 
Human peripheral blood primary monocytes were isolated and differentiated to 
macrophage for 7 days using M-CSF (A).  The macrophages were cultured with medium 
alone (M0), medium with LPS and IFN-γ (M1), IL-4 and IL-13 (M2), EVs from HSC-3 or SCC-
25 cells (B). Expression of M1 markers (CXCL9 and CXCL10) and M2 markers (CCL17, CCL18 
and CCL22) was evaluated using q-PCR (C). Scale bar=200 µm.  
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Morphologically, M1 macrophages were spherical and M2 macrophages were more 
cone-shaped. Upon the treatment of HSC-3 and SCC-25 EVs, most of the 
macrophages looked like spindle-shaped M0. While some of them had M2 
representative cone-shaped morphology (Fig.11B). 
Quantitative real time-PCR of M1 and M2 macrophage markers was done to evaluate 
the polarization effects of EVs on macrophages. We included CXCL10 and CXCL9 as 
M1 markers, and CCL17, CCL18 and CCL22 as M2 markers. The outcome of q-PCR 
showed no significant difference of the expression of any phenotypic markers 
between M0 control and macrophages treated with EVs from any cell lines (Fig.11C). 
4.5. Modulation of cytotoxic activity of CD8+ T cells and NK cells by OTSCC cell EVs 
Human primary CD8+ T cells and NK cells were isolated from blood of three healthy 
donors and treated with EVs of HSC-3 or SCC-25 cells for 24 hours. Then the CD8+ T 
cells and NK cells were co-cultured with HSC-3 and SCC-25 cells to check their 
cytotoxic activity. Apoptosis of OTSCC cells induced by CD8+ T cells and NK cells was 
measured over time (Supplement 2). 
Overall the cytotoxic activity of CD8+ T cells and NK cells were upregulated by 
treatment of OTSCC cells EVs (Fig.12). However, this upregulation was not seen in 
every circumstances. It varied from donor to donor, between different sources of 
EVs, different cytotoxic cells and different OTSCC cell lines they acted on. 
In the case of donor 1, cytotoxic activity of CD8+ T cells against HSC-3 cells was 
upregulated by treatment of SCC-25 EVs, but the treatment had no effect on the 
killing activity against their source cancer cells, SCC-25 (Fig.12A, D). For donor 2, 
HSC-3 EVs were promoting the killing against only HSC-3 cells (Fig.12B, E). 
Meanwhile, for donor 3, EVs from both HSC-3 and SCC-25 cells were increasing the 
cytotoxic activity of CD8+ T cells against both OTSCC cell lines (Fig.12C, F). 
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Fig.12 Modulation of OTSCC cells EVs on cytotoxic activity of CD8+ T cells and NK cells. 
Cytotoxic CD8+ T cells and CD56+ NK cells were and incubated with medium alone, or 
medium with EVs from HSC-3 and SCC-25 cells for 24 hours. Then the cytotoxic cells were 
co-cultured with HSC-3 or SCC-25 cells for 5 days and the number of apoptotic cancer cells 
were counted over time using IncuCyte Live-Cell Imaging System. 
As for NK cells, after treatment with SCC-25 EVs, cytotoxic activity of NK cells to kill 
both HSC-3 and SCC-25 was enhanced for donor 2 and 3 but not donor 1 (Fig.12H, I, 
K and L). HSC-3 EVs was only positively effective for NK cells killing ability against 
HSC-3 cells in donor 3 (Fig.12I). 
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On the other hand, cytotoxic activity of CD8+ T cells against SCC-25 was even 
reduced by treatment of HSC-3 EVs for donor 1 (Fig.12D). SCC-25 EVs also reduced 
NK cells killing ability against both cell lines for donor 1 (Fig.12G, J). 
 Donor 1 Donor 2 Donor 3 
CD8+ kill HSC-3 SCC-25(+) HSC-3(+) HSC-3(+), SCC-25(+) 
CD8+ kill SCC-25 HSC-3(-) / HSC-3(+), SCC-25(+) 
NK kill HSC-3 SCC-25(-) SCC-25(+) HSC-3(+), SCC-25(+) 
NK kill SCC-25 SCC-25(-) SCC-25(+) SCC-25(+) 
Table 4. Modulatory effects of OTSCC cells EVs on cytotoxic activity of CD8+ T cells and 
NK cells against OTSCC cell lines. ‘SCC-25(+)/(-)’: SCC-25 EVs increased/ decreased 
cytotoxic activity; ‘HSC-3(+)/(-)’: HSC-3 EVs increased/decreased cytotoxic activity; ‘/’: EVs 
of neither cell lines had modulatory effect on cytotoxic activity. 
The effects of EVs on the cytotoxic activity of CD8+ T cells and NK cells against OTSCC 
cell lines are briefly displayed in Table 4. To summarize up, EVs derived from more 
aggressive HSC-3 cells stimulated the increase of cytotoxic activity of inflammatory 
cells in 4 out of 12 circumstances (Fig.12B, C, F and I), while EVs from less aggressive 
SCC-25 cells showed this effect in 7 out of 12 (Fig. 12A, C, F, H, I, K and L). 
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5. Discussion 
This study mainly investigated the crosstalk between OTSCC cells and inflammatory 
cells via extracellular cytokine/chemokine secretion, EVs production, or direct cell-
cell contact. Firstly, with a 3D organotypic myoma model, we co-cultured OTSCC 
cells and MNCs and looked into the ability of the latter to affect the proliferation and 
invasion of the former, as well as the chemotaxis effect by the former attracting the 
latter into myoma tissue. In the second part of the study, we studied how EVs 
derived from OTSCC cells modulated the phenotypes and cytotoxic activity of 
selected inflammatory cells. The findings and significance of this study are discussed 
as following. 
5.1. Effects of inflammatory cells on proliferation, invasion and migration of OTSCC 
cells 
5.1.1. In vitro myoma model 
We used an in vitro model made of human uterine leiomyoma which mimics the TME 
of OTSCC. Myoma is a more authentic alternative to traditionally used model 
composed of type I collagen and fibroblasts (Nurmenniemi et al., 2009; Nyström et 
al., 2005).  
Compared with collagen model, myoma contains more various cell types and ECM 
components. Besides, in myoma, carcinoma cells behave more closely to how they 
do in vivo, and molecular activities that happen in TME such as MMP production and 
collagen degradation are enhanced (Nurmenniemi et al., 2009).  
As discussed in literature review part, inflammatory cells present in TME and play a 
complicated and subtle role which is still of great debate. They can recognize certain 
antigen of cancer cells and induce cell death, or produce anti-tumor mediators 
(Mantovani et al., 2010; Ruddon, 2007). On the other hand, cancer cell recruit some 
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inflammatory cells to downregulate the immune surveillance and keep a TME 
favoring tumor progression (Qian & Pollard, 2010). 
To study the mutual effects of cancer cells and inflammatory cells in vitro, it is 
important to co-culture them in an environment where they act as in vivo to a 
maximal extent, both physically and physiologically. As the fact that cancer cells of 
solid tumor are adherent while most immune cells are non-adherent, a multiphasic 
co-culture model is needed to provide a solid matrix that resembles TME as well as 
a medium for non-adherent immune cells. The myoma co-culture model used in this 
study meets the requirements. 
5.1.2. Effects of activated MNCs on proliferation, invasion and migration of OTSCC 
cells 
In the co-culture experiment, activated human peripheral MNCs significantly 
reduced proliferation of both HSC-3 and SCC-25 cells. This reduction was likely to 
be caused by certain extracellular signals such as anti-tumor mediators produced by 
MNCs and permeating into myoma tissue. Since CD8+ cells were only found at the 
bottom of the myoma discs while CD45+ cells distributed in all areas of the myoma, 
it seemed hard for CD8+ cells to kill cancer cells by releasing granules or Fas/Fasl 
interaction, thus other MNCs might turn to be predominant role to exert reduction 
effect on cancer cells proliferation in this case. 
We saw the non-activated MNCs, which spontaneously produce little cytokines 
(Baran et al., 2001), had no significant effects on proliferation or any invasion 
parameters of OTSCC cells. The distinct performance of non-activated and activated 
MNCs indicates that the activation is the key and premise of MNCs function. Besides, 
activated T cells only partially showed inhibitory effects on proliferation of SCC-25 
cells, which implies the considerable importance of other components of MNCs such 
as B cells, NK cells and monocytes in cancer immunity. 
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As for invasion and migration sections, the only significant effect witnessed in the 
experiment was the reduction of HSC-3 cells invasion area by activated MNCs. MNCs 
appeared to have little influence on invasion depth or migration of OTSCC cells. In 
fact, it was somehow obvious that the migration of OTSCC in the wound closing 
assay was impeded by PMA and ionomycin, the activators for MNCs, which could 
induce apoptosis of the migrating cancer cells (Han et al., 2013). 
After all, as described earlier, cancer cells are adherent while immune cells are 
mostly non-adherent. This difference of adherence might cause insufficient 
interaction between two types of cells in our wound healing assays. The harmful 
MNCs activators (PMA and ionomycin) were also obstacle to acquire persuasive 
results. 
In general, activated MNCs inhibited proliferation of both OTSCC cell lines and 
invasion area of only HSC-3 cells, but showed no influence on invasion depth or 
migration of OTSCC cells in this study. This may reveal the fact that these 
inflammatory cells are important in controlling tumor growth, yet they have little 
restriction effect of invasion and metastasis (Fukano et al., 1997).  
5.1.3. Correlation between OTSCC cell proliferation and invasion 
For both HSC-3 and SCC-25 cells, proliferation was positively correlated with 
invasion area, but not correlated with invasion depth, suggesting thriving cancer cell 
reproduction doesn’t necessarily mean aggressive invasion and metastasis.  
It will be easier to understand this conclusion in consideration of different clinical 
growth types (superficial, exophytic and endophytic) of OTSCC. It’s also in line with 
the finding by Hideo Fukano et al. that invasion mode and depth, other than tumor 
size, were two significant predictors of OTSCC regional metastasis (1997).  
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5.2. OTSCC cell chemotaxis attraction of inflammatory cells to infiltrate into 
myoma tissue 
Cancer cells are a chemokine source which recruit various populations of immune 
cells to infiltrate via chemokines secretion, manipulating a particular immune TME 
(Koizumi et al., 2007). In our co-culture model, the chemotaxis of OTSCC cells to 
attract MNCs to infiltrate into myoma tissue in different conditions was studied.  
In the IHC stained myoma section, more CD45+ cells were found in myoma only 
when activated MNCs were added, at least from microscopic observation. However, 
this increase was not statistically significant for both OTSCC cell lines, perhaps due 
to the variation of the number of CD45+ cells between samples. On the other hand, 
for HSC-3 experiment, significantly more CD8+ T cells were infiltrating into myoma 
only when activated MNCs were added.  
These findings suggest the OTSCC cells via chemokines recruit MNCs selectively. 
Considering the facts that dense lymphocytic infiltration correlated with better 
prognosis of OTSCC (Lundqvist et al., 2012), and CD8+ T cells infiltration was also 
predictive for good prognosis for colorectal cancer (Naito et al., 1998), the activated 
MNCs added here may played an anti-tumor role of ‘good inflammation’ from this 
perspective.  
Besides, chemotaxis ability varies between OTSCC cell lines. Although for more 
aggressive HSC-3 we witnessed significant difference while not in SCC-25, whether 
aggressiveness and chemotaxis tension are correlated is unknown.  
The majority of CD8+ T cells were located at the bottom of myomas. They appeared 
to be unable to migrate towards OTSCC cells, perhaps because of a relatively more 
powerful chemotaxis attraction from the MNCs in the bottom of this co-culture 
model (Roussos et al., 2011). Meanwhile, the CD8+ T cells were mostly found close 
to blood vessels, suggesting they infiltrated into myoma through the vessels. This 
may provide another explanation of the accumulation of CD8+ T cells at the bottom, 
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which is the loss of inflammatory vascular responses in myoma such as vascular 
permeability increase and oncotic pressure change. 
There have been several methods and models to study different cell migrations in 
cancer, such as in vitro 2D chemotaxis assays, Transwell assay, 3D culture and other 
in vivo methods (Roussos et al., 2011). The results of this thesis also prove the 
practicability of myoma model especially to mimic the environment in vivo to study 
immune cells recruitment. The advantages of myoma models include better 
simulation of TME as well as organotypic structure, and convenience of imaging. 
5.3. Effects of OTSCC cell-derived EVs on different populations of inflammatory 
cells 
It has been widely evidenced that cancer cells can secret extracellular vesicles to 
trigger cellular response and modulate activity and phenotype of TME cells (Kalluri, 
2016). An in vitro study showed that EVs of OTSCC cells (HSC-3) probably induced 
the transition from CaDEC fibroblastic cells to cancer associated fibroblast (CAF)-
like cells (Dayan et al., 2012).  
However, there is barely research looking into the function of OTSCC-derived EVs 
on particular populations of immune cells. Here, our in vitro experiments in this 
thesis study firstly focused on how OTSCC-derived EVs influence macrophage 
polarization and cytotoxic activity of CD8+ T cells and NK cells. 
5.3.1. OTSCC cell-derived EVs and macrophage polarization 
TAMs, as a significant component of TME cell community, are generally associated 
with cancer-promoting activities in most of the cases (Qian & Pollard, 2010). The 
induced polarization of TAMs from the anti-tumor phenotype M1 towards the pro-
tumor phenotype M2 is suggested as a strategy of cancer cells to maintain an 
immune ecosystem that favors cancer cells (Mantovani et al., 2010).  
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An earlier in vitro research revealed the ability of breast cancer cell-secreted factors 
to educate human primary macrophages to differentiate towards M2 phenotype 
(Sousa et al., 2015). Another study got similar result with colorectal cancer cells and 
human monocytic cell line, THP-1 cells (Wu et al., 2014). Both experiment were 
conducted using cancer cell conditioned medium (supernatant).  
In this thesis study, we aimed to verify whether OTSCC cell-derived EVs have the 
same educational ability. A pilot experiment indicated that HSC-3 EVs incubation 
polarized THP-1 cells towards M2 phenotype (data not shown). While EVs derived 
from both HSC-3 and SCC-25 cells did not polarize human primary macrophages 
towards any phenotypes. 
Firstly, the failure of OTSCC cell-derived EVs to educate primary macrophage may 
be explained by the fact that the isolated EVs lack a variety of cytokines and growth 
factors present in the cancer cell conditioned medium, which results in the 
weakness of EVs in macrophage polarization (Mantovani et al., 2010). 
Besides, we saw difference in the responses of THP-1 cells and primary 
macrophages to EVs treatment, which is in agreement with a previous finding that 
THP-1 cells were potently more responsive to toxic stimulation than primary 
monocytes (Heil et al., 2002). These suggest that THP-1 cells are not predictive 
enough for representing primary macrophages in terms of secretory response, and 
the results derived from THP-1 cells should always be followed by verification of the 
corresponding primary cells. 
5.3.2. OTSCC cell-derived EVs and cytotoxic activity of CD8+ T cells and NK cells 
As cancer cell EVs carry antigenic materials (proteins, nucleic acids and membrane-
derived lipids from parental cells), they have been used as vaccination in research 
of in vivo murine cancer models and in vitro human immune cells, and showed 
potent immunogenic effects (Kunigelis & Graner, 2015; Wolfers et al., 2001; Andre 
et al., 2002). In this study, we treated two types of cytotoxic inflammatory cells, 
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namely CD8+ T cells and NK cells from three healthy donors, with EVs derived from 
two OTSCC cell lines (HSC-3 and SCC-25) of different aggressiveness, and then the 
treated cytotoxic cells were co-cultured with the two OTSCC cell lines to check 
whether their cytotoxic activity had been modulated by EVs. 
We discovered that OTSCC cell-derived EVs to certain extent modulated cytotoxic 
activity of CD8+ T cells and NK cells, but the direction and responsiveness of 
modulation varied from case to case and depended on several factors. These factors 
included inflammatory cell sources (three donors), cytotoxic cell types (CD8+ T cells 
or NK cells), EVs sources (HSC-3 or SCC-25) and also targeted cell lines (HSC-3 or 
SCC-25) that were against. The diverse outcome in our experiment showed not only 
the individually distinguishing immune system phenotypes among different people, 
but also the controversial role (immune stimulator or suppressor) of cancer cell-
derived EVs in cancer immunity. 
In summary, as discussed in the review by Kunigelis & Graner (2015), the context 
where cancer cell EVs encounter immune cells, including both extracellular 
environment and specific immune cell type and condition, may be deciding factors 
of the immune response to cancer mediation by EVs. 
  
49 
 
6. Conclusion 
This study investigated the crosstalk between OTSCC cells and inflammatory cells in 
an in vitro condition. We found that activated human peripheral blood MNCs 
significantly reduced proliferation of both OTSCC cell lines, and invasion area of only 
HSC-3. None of the inflammatory cells in the experiment had any effect on invasion 
depth and migration of OTSCC cells. On the other hand, OTSCC cell-derived EVs 
didn’t influence macrophage polarization, but had heterogeneous modulating 
effects on cytotoxic activity of CD8+ T cells and NK cells. 
In conclusion, although we detected effects of OTSCC cells and inflammatory cells on 
each other by secreted molecule mediators or EVs, the results were not uniform and 
varied in different OTSCC cell lines or inflammatory cell populations and sources. 
The outcome of the study emphasizes the importance of a personalized design of 
cancer treatment, which takes other components in TME such as immune cells and 
EVs into consideration. A pre-treatment in vitro test of patient’s cancer cells 
response to chemoradiotherapy or drug in the presence of patient’s serum may be 
useful. 
The 3D organotypic model used in the study was a highlight as it offered a better 
simulation compared with previous 2D models or materials derived from murine, 
especially for studying cell activities like invasion and infiltration. Besides, it is 
suitable for co-culturing of different cell types in TME, thus providing a possible 
approach for the pre-treatment in vitro test of cancer patients. 
Some improvement and further investigation that can be addressed in future are: 
 The infiltration of immunosuppressive cells such as Treg upon the chemotaxis 
attraction from OTSCC cells. 
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 An OTSCC cell migration model that better mimics the authentic in vivo situation, 
and an inflammatory cell recruitment model that takes circulation into 
consideration 
 The molecular mechanism of the crosstalk of OTSCC cells and inflammatory cells 
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Supplements 
Supplement 1. HSC-3 cells migration in scratch wound healing assay 
https://www.youtube.com/watch?v=LtcWEoGa5cc 
Supplement 2. CD8+ T cells killing HSC-3 cells in cell killing assay 
https://www.youtube.com/watch?v=NQE4gfLo4mA 
 
